A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Recruiting now NCT06433752
Run by TG Therapeutics, Inc. · for 18 and older · All sexes
What this study is about
The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the real-world setting
Who can join (things the study team will check)
✅ You may be able to join if…
- Confirmed Multiple Sclerosis (MS) diagnosis.
- Participants who have not received any BRIUMVI® (ublituximab-xiiy) infusion prior to study start. Participants who have been prescribed BRIUMVI® (ublituximab-xiiy) but have not yet received their first infusion on Day 1 of 150 milligrams (mg) can be included.
🚫 You may not be able to join if…
- Have received any live or live-attenuated vaccines (including for varicella-zoster virus or measles) within 4 weeks prior to first BRIUMVI® (ublituximab-xiiy) administration or any non-live vaccines within 2 weeks prior to first BRIUMVI® (ublituximab-xiiy) administration.
- Any active infection (e.g., active Hepatitis B virus [HBV])
- Concurrent participation in any interventional MS trials, or planned concurrent treatment with other Multiple Sclerosis Disease Modifying Therapy (MS DMT) during the study period.
Where this trial is running
- TG Therapeutics Investigational Trial Site, Birmingham, Alabama, United States
- TG Therapeutics Investigational Trial Site, Huntsville, Alabama, United States
- TG Therapeutics Investigational Trial Site, Mobile, Alabama, United States
- TG Therapeutics Investigational Trial Site, Gilbert, Arizona, United States
- TG Therapeutics Investigational Trial Site, Phoenix, Arizona, United States
- TG Therapeutics Investigational Trial Site, Scottsdale, Arizona, United States
- TG Therapeutics Investigational Trial Site, Fresno, California, United States
- TG Therapeutics Investigational Trial Site, Newport Beach, California, United States
- TG Therapeutics Investigational Trial Site, Orange, California, United States
- TG Therapeutics Investigational Trial Site, West Hollywood, California, United States
- TG Therapeutics Investigational Trial Site, Aurora, Colorado, United States
- TG Therapeutics Investigational Trial Site, Basalt, Colorado, United States
+ 78 more sites.
Who to contact
TG Therapeutics Clinical Support Team · 1-877-575-8489 · clinicalsupport@tgtxinc.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06433752.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.